Robotic versus Laparoscopic Liver Resection in Various Settings: An International Multicenter Propensity Score Matched Study of 10.075 Patients.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
14 Mar 2024
Historique:
medline: 14 3 2024
pubmed: 14 3 2024
entrez: 14 3 2024
Statut: aheadofprint

Résumé

The aim of this study was to compare the perioperative outcomes of robotic liver surgery (RLS) and laparoscopic liver surgery (LLS) in various settings. Clear advantages of RLS over LLS have rarely been demonstrated, and the associated costs of robotic surgery are generally higher than those of laparoscopic surgery. Therefore, the exact role of the robotic approach in minimally invasive liver surgery remains to be defined. In this international retrospective cohort study, the outcomes of patients who underwent RLS and LLS for all indications between 2009 and 2021 in 34 hepatobiliary referral centers were compared. Subgroup analyses were performed to compare both approaches across several types of procedures: minor resections in the anterolateral (2, 3, 4b, 5, and 6) or posterosuperior segments (1, 4a, 7, 8), and major resections (≥3 contiguous segments). Propensity score matching (PSM) was used to mitigate the influence of selection bias. The primary outcome was textbook outcome in liver surgery (TOLS), previously defined as the absence of intraoperative incidents ≥grade 2, postoperative bile leak ≥grade B, severe morbidity, readmission, and 90-day or in-hospital mortality with the presence of an R0 resection margin in case of malignancy. The absence of a prolonged length of stay was added to define TOLS+. Among the 10.075 included patients, 1.507 underwent RLS and 8.568 LLS. After PSM, both groups constituted 1.505 patients. RLS was associated with higher rates of TOLS (78.3% vs. 71.8%, P<0.001) and TOLS+ (55% vs. 50.4%, P=0.026), less Pringle usage (39.1% vs. 47.1%, P<0.001), blood loss (100 vs. 200 milliliters, P<0.001), transfusions (4.9% vs. 7.9%, P=0.003), conversions (2.7% vs 8.8%, P<0.001), overall morbidity (19.3% vs. 25.7%, P<0.001) and R0 resection margins (89.8% vs. 86%, P=0.015), but longer operative times (190 vs. 210 min, P=0.015). In the subgroups, RLS tended to have higher TOLS rates, compared to LLS, for minor resections in the posterosuperior segments (n=431 per group, 75.9% vs. 71.2%, P=0.184) and major resections (n=321 per group, 72.9% vs. 67.5%, P=0.086), although these differences did not reach statistical significance. While both producing excellent outcomes, RLS might facilitate slightly higher TOLS rates than LLS.

Sections du résumé

OBJECTIVE OBJECTIVE
The aim of this study was to compare the perioperative outcomes of robotic liver surgery (RLS) and laparoscopic liver surgery (LLS) in various settings.
SUMMARY BACKGROUND DATA BACKGROUND
Clear advantages of RLS over LLS have rarely been demonstrated, and the associated costs of robotic surgery are generally higher than those of laparoscopic surgery. Therefore, the exact role of the robotic approach in minimally invasive liver surgery remains to be defined.
METHODS METHODS
In this international retrospective cohort study, the outcomes of patients who underwent RLS and LLS for all indications between 2009 and 2021 in 34 hepatobiliary referral centers were compared. Subgroup analyses were performed to compare both approaches across several types of procedures: minor resections in the anterolateral (2, 3, 4b, 5, and 6) or posterosuperior segments (1, 4a, 7, 8), and major resections (≥3 contiguous segments). Propensity score matching (PSM) was used to mitigate the influence of selection bias. The primary outcome was textbook outcome in liver surgery (TOLS), previously defined as the absence of intraoperative incidents ≥grade 2, postoperative bile leak ≥grade B, severe morbidity, readmission, and 90-day or in-hospital mortality with the presence of an R0 resection margin in case of malignancy. The absence of a prolonged length of stay was added to define TOLS+.
RESULTS RESULTS
Among the 10.075 included patients, 1.507 underwent RLS and 8.568 LLS. After PSM, both groups constituted 1.505 patients. RLS was associated with higher rates of TOLS (78.3% vs. 71.8%, P<0.001) and TOLS+ (55% vs. 50.4%, P=0.026), less Pringle usage (39.1% vs. 47.1%, P<0.001), blood loss (100 vs. 200 milliliters, P<0.001), transfusions (4.9% vs. 7.9%, P=0.003), conversions (2.7% vs 8.8%, P<0.001), overall morbidity (19.3% vs. 25.7%, P<0.001) and R0 resection margins (89.8% vs. 86%, P=0.015), but longer operative times (190 vs. 210 min, P=0.015). In the subgroups, RLS tended to have higher TOLS rates, compared to LLS, for minor resections in the posterosuperior segments (n=431 per group, 75.9% vs. 71.2%, P=0.184) and major resections (n=321 per group, 72.9% vs. 67.5%, P=0.086), although these differences did not reach statistical significance.
CONCLUSIONS CONCLUSIONS
While both producing excellent outcomes, RLS might facilitate slightly higher TOLS rates than LLS.

Identifiants

pubmed: 38482665
doi: 10.1097/SLA.0000000000006267
pii: 00000658-990000000-00807
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

COI/Disclosures: The authors have no related conflicts of interest to declare. However, outside of the submitted work Mohammed Abu Hilal and Marc Besselink received grants from Medtronic GmbH, Intuitive Surgical Inc and Johnson&Johnson Medical GmbH for investigator-initiated studies. Santi Lopez-Ben reported received fees from Baxter, Olympus and Johnson & Johnson. Moritz Schmelzle reported received fees from Merck Serono GmbH, Bayer AG, ERBE Elektromedizin GmbH, Amgen Inc., AstraZeneca, Avateramedical GmbH, Johnson&Johnson Medical GmbH, TakedaPharmaceutical Limited, Olympus K.K., Medtronic GmbH, Intuitive Surgical Inc., Corzamedical, Baxter Int Inc. Åsmund Avdem Fretland reported speaker’s honoraria from Bayer and Olympus. Fernando Rotellar reported speakers honoraria from Olympus. Conflicts of interest and source of funding: No related conflicts of interest or funding.

Auteurs

Jasper P Sijberden (JP)

Department of Surgery, Poliambulanza Foundation Hospital, Brescia, Italy.
Amsterdam UMC location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

Tijs J Hoogteijling (TJ)

Department of Surgery, Poliambulanza Foundation Hospital, Brescia, Italy.
Amsterdam UMC location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

Davit Aghayan (D)

The Intervention Centre and Department of HPB surgery, Oslo University Hospital and Institute of Medicine, University of Oslo, Oslo, Norway.

Francesca Ratti (F)

Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.

Ek-Khoon Tan (EK)

Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore.

Victoria Morrison-Jones (V)

Department of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.

Jacopo Lanari (J)

Department of Surgical, Oncological and Gastroenterological Sciences, General Surgery 2, Hepatopancreatobiliary Surgery and Liver Transplantation, Padua University Hospital, Padua, Italy.

Louis Haentjens (L)

Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, Kortrijk, Belgium.

Kongyuan Wei (K)

Faculty of Hepatopancreatobiliary Surgery, the First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.

Stylianos Tzedakis (S)

Department of Digestive, Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Université Paris Descartes, Paris 75014, France.

John Martinie (J)

Division of HPB Surgery, Department of Surgery, Carolinas Medical Center, Atrium Health, Charlotte, North Carolina, USA.

Daniel Osei Bordom (D)

Liver unit, Queen Elizabeth Hospital, Birmingham, United Kingdom.

Giuseppe Zimmitti (G)

Department of Surgery, Poliambulanza Foundation Hospital, Brescia, Italy.

Kaitlyn Crespo (K)

Digestive Health Institute, AdventHealth Tampa, Tampa, Florida, USA.

Paolo Magistri (P)

Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy.

Nadia Russolillo (N)

Department of General and Oncological Surgery, Umberto I Mauriziano Hospital, Largo Turati 62, 10128, Turin, Italy.

Simone Conci (S)

Department of Surgery, University of Verona, Verona, Italy.

Burak Görgec (B)

Amsterdam UMC location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

Andrea Benedetti Cacciaguerra (A)

Hepatobiliary and Abdominal Transplantation Surgery, Department of Experimental and Clinical Medicine, Riuniti Hospital, Polytechnic University of Marche, Ancona, Italy.

Daniel D'Souza (D)

Department of Surgery, McMaster University, Hamilton, Ontario, Canada.

Gabriel Zozaya (G)

HPB and Liver Transplantation Unit, Department of Surgery, University Clinic, Universidad de Navarra; Institute of Health Research of Navarra (IdisNA), Pamplona, Spain.

Cèlia Caula (C)

Servei de Cirurgia General i Digestiva, Hospital Doctor Josep Trueta de Girona, Girona, Catalonia, Spain.

David Geller (D)

Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Ricardo Robles Campos (R)

Department of General, Visceral and Transplantation Surgery, Clinic and University Hospital Virgen de la Arrixaca, IMIB-ARRIXACA, El Palmar, Murcia, Spain.

Roland Croner (R)

Department of General, Visceral, Vascular and Transplant Surgery, University Hospital Magdeburg, Magdeburg, Germany.

Shafiq Rehman (S)

Department of Surgery, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

Elio Jovine (E)

Department of Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Mikhail Efanov (M)

Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Scientific Center, Moscow, Russia.

Adnan Alseidi (A)

Department of Surgery, Virginia Mason Medical Center, Seattle, USA and Department of Surgery, University of California San Francisco, California, USA.

Riccardo Memeo (R)

Hepato-Pancreato-Biliary Surgery Unit, Miulli Hospital, Acquaviva delle Fonti, Bari, Italy.

Ibrahim Dagher (I)

Department of Digestive Minimally Invasive Surgery, Antoine Béclère Hospital, Paris, France.

Felice Giuliante (F)

Chirurgia Epatobiliare, Università Cattolica del Sacro Cuore-IRCCS, Rome, Italy.

Ernesto Sparrelid (E)

Division of Surgery, Department for Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Jawad Ahmad (J)

University Hospitals Coventry and Warwickshire, Clifford Bridges Road, Coventry, United Kingdom.

Tom Gallagher (T)

St. Vincent's University Hospital, Elm Park, Dublin, Ireland.

Moritz Schmelzle (M)

Department of General, Visceral and Transplant Surgery, Medizinische Hochschule Hannover, Hannover, Germany.

Rutger-Jan Swijnenburg (RJ)

Amsterdam UMC location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

Åsmund Avdem Fretland (ÅA)

The Intervention Centre and Department of HPB surgery, Oslo University Hospital and Institute of Medicine, University of Oslo, Oslo, Norway.

Federica Cipriani (F)

Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.

Ye-Xin Koh (YX)

Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore.

Steven White (S)

Department of General, Visceral, Vascular and Transplant Surgery, University Hospital Magdeburg, Magdeburg, Germany.

Santi Lopez Ben (S)

Servei de Cirurgia General i Digestiva, Hospital Doctor Josep Trueta de Girona, Girona, Catalonia, Spain.

Fernando Rotellar (F)

HPB and Liver Transplantation Unit, Department of Surgery, University Clinic, Universidad de Navarra; Institute of Health Research of Navarra (IdisNA), Pamplona, Spain.

Pablo E Serrano (PE)

Department of Surgery, McMaster University, Hamilton, Ontario, Canada.

Marco Vivarelli (M)

Hepatobiliary and Abdominal Transplantation Surgery, Department of Experimental and Clinical Medicine, Riuniti Hospital, Polytechnic University of Marche, Ancona, Italy.

Andrea Ruzzenente (A)

Department of Surgery, University of Verona, Verona, Italy.

Alessandro Ferrero (A)

Department of General and Oncological Surgery, Umberto I Mauriziano Hospital, Largo Turati 62, 10128, Turin, Italy.

Fabrizio Di Benedetto (F)

Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy.

Marc G Besselink (MG)

Amsterdam UMC location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

Iswanto Sucandy (I)

Digestive Health Institute, AdventHealth Tampa, Tampa, Florida, USA.

Robert P Sutcliffe (RP)

Liver unit, Queen Elizabeth Hospital, Birmingham, United Kingdom.

Dionisios Vrochides (D)

Division of Abdominal Transplantation, Department of Surgery, Carolinas Medical Center, Atrium Health, Charlotte, North Carolina, USA.

David Fuks (D)

Department of Digestive, Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Université Paris Descartes, Paris 75014, France.

Rong Liu (R)

Faculty of Hepatopancreatobiliary Surgery, the First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.

Mathieu D'Hondt (M)

Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, Kortrijk, Belgium.

Umberto Cillo (U)

Department of Surgical, Oncological and Gastroenterological Sciences, General Surgery 2, Hepatopancreatobiliary Surgery and Liver Transplantation, Padua University Hospital, Padua, Italy.

John N Primrose (JN)

Department of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.

Brian K P Goh (BKP)

Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore.
Surgery Academic Clinical Programme, Duke-National University of Singapore Medical School, Singapore, Singapore.

Luca A Aldrighetti (LA)

Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.

Bjørn Edwin (B)

The Intervention Centre and Department of HPB surgery, Oslo University Hospital and Institute of Medicine, University of Oslo, Oslo, Norway.

Mohammad Abu Hilal (M)

Department of Surgery, Poliambulanza Foundation Hospital, Brescia, Italy.
Department of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.

Classifications MeSH